Biotech Showcase
Join us virtually
January 10–12, 2022 &January 17–19, 2022

Ted Haack
VP at Lattice Point Consulting


Ted Haack joined LatticePoint in July 2016 as Vice President.

He provides advisory services to early-stage genetic disease  companies and has advised on market access, EMA Adaptive Pathways, international expansion, talent acquisition, and key customer relationships.  Prior to consulting, he spent 17 years working in the pharmaceutical industry and headed the Market Access function for Genzyme’s Rare Disease Business Unit and Pfizer’s Head of Head of Market Access, Primary Care BU.  Before joining Pfizer, he spent 7 years at Schering-Plough in various regional and affiliate finance roles.  Ted began his career at Deloitte & Touche, including two years in Frankfurt, Germany and is a qualified SEC Audit Committee Financial Expert.  He has a BS degree in accounting from Villanova University, a Master of Arts in International Affairs from The Fletcher School of Law & Diplomacy at Tufts University, and an MBA from the Leonard N. Stern School of Business at New York University. He speaks fluent German in addition to his native English.

Agenda Sessions

  • The Road to an RMAT (Regenerative Medicine Advanced Therapy) FDA Approval

    On Demand